bioAffinity Technologies Files 8-K with Material Agreements
Ticker: BIAFW · Form: 8-K · Filed: Oct 21, 2024 · CIK: 1712762
Sentiment: neutral
Topics: material-agreement, equity-sale, corporate-action
Related Tickers: BIAF
TL;DR
BIAF filed an 8-K detailing material agreements and equity sales - big moves happening.
AI Summary
On October 17, 2024, bioAffinity Technologies, Inc. entered into a material definitive agreement, likely related to financing or a strategic partnership. The company also reported on unregistered sales of equity securities and amendments to its articles of incorporation or bylaws. This filing indicates significant corporate activity and potential changes in the company's structure or financial standing.
Why It Matters
This filing signals significant corporate actions by bioAffinity Technologies, Inc., which could impact its financial structure, strategic direction, and shareholder value.
Risk Assessment
Risk Level: medium — The filing indicates material definitive agreements and unregistered sales of equity, which can introduce financial and operational risks.
Key Players & Entities
- bioAffinity Technologies, Inc. (company) — Registrant
- October 17, 2024 (date) — Earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-41463 (identifier) — SEC File Number
FAQ
What is the nature of the material definitive agreement entered into by bioAffinity Technologies, Inc. on October 17, 2024?
The filing indicates the entry into a material definitive agreement, but the specific details of this agreement are not provided in the provided text.
What type of equity securities were sold unregistered by bioAffinity Technologies, Inc.?
The filing mentions unregistered sales of equity securities, but the specific type and amount are not detailed in the provided text.
What amendments were made to bioAffinity Technologies, Inc.'s articles of incorporation or bylaws?
The filing notes amendments to articles of incorporation or bylaws, but the specific changes are not detailed in the provided text.
What is the primary business of bioAffinity Technologies, Inc. according to the filing?
bioAffinity Technologies, Inc. is classified under SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731].
When is bioAffinity Technologies, Inc.'s fiscal year end?
bioAffinity Technologies, Inc.'s fiscal year ends on December 31.
Filing Stats: 3,121 words · 12 min read · ~10 pages · Grade level 14.9 · Accepted 2024-10-21 09:30:43
Key Financial Figures
- $0.007 — ch registered Common Stock, par value $0.007 per share BIAF The Nasdaq Stock Mar
- $1.50 — ant Shares"), with an exercise price of $1.50. Such registered direct offering and co
- $2,662,782 — eds from the Offerings of approximately $2,662,782, excluding any proceeds that may be rec
- $75,000 — t-of-pocket expenses up to a maximum of $75,000. As additional compensation to the Plac
- $1 — at an exercise price per share equal to $1.50, which is equal to the exercise pric
Filing Documents
- form8-k.htm (8-K) — 77KB
- ex1-1.htm (EX-1.1) — 150KB
- ex3-1.htm (EX-3.1) — 5KB
- ex4-1.htm (EX-4.1) — 122KB
- ex4-2.htm (EX-4.2) — 115KB
- ex5-1.htm (EX-5.1) — 13KB
- ex10-1.htm (EX-10.1) — 265KB
- ex10-2.htm (EX-10.2) — 18KB
- ex5-1_001.jpg (GRAPHIC) — 214KB
- ex99-1.htm (EX-99.1) — 18KB
- ex99-1_001.jpg (GRAPHIC) — 6KB
- ex99-1_002.jpg (GRAPHIC) — 7KB
- 0001493152-24-041721.txt ( ) — 1489KB
- biaf-20241017.xsd (EX-101.SCH) — 4KB
- biaf-20241017_def.xml (EX-101.DEF) — 29KB
- biaf-20241017_lab.xml (EX-101.LAB) — 36KB
- biaf-20241017_pre.xml (EX-101.PRE) — 26KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 21, 2024 BIOAFFINITY TECHNOLOGIES, INC. (Registrant) By: /s/ Maria Zannes Name: Maria Zannes Title: President and Chief Executive Officer